Effects of RAAS Inhibitors in Patients with Kidney Disease

Zhang, Fan; Liu, Hong; Liu, Di; Liu, Yexin; Li, Huiqiong; Tan, Xiao; Liu, Fuyou; Peng, Youming; Zhang, Hongqing

doi:10.1007/s11906-017-0771-9

Cited by 71 publications

(42 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Progression to DN in diabetic patients is a very complicated process and is due to multiple factors, and previous reviews have discussed this topic extensively (Remuzzi et al, 2005;Piero et al, 2010;Zhang et al, 2017). As a summary, in diabetic settings, metabolic dysregulation leads to the alteration of kidney hemodynamics, promotes glomerulosclerosis, tubulointerstitial inflammation, and fibrosis.…”

Section: Diabetic Nephropathy Progressionmentioning

confidence: 99%

Interactions Among Non-Coding RNAs in Diabetic Nephropathy

et al. 2020

View full text Add to dashboard Cite

Diabetic Nephropathy (DN) is the most common cause of End-stage renal disease (ESRD). Although various treatments and diagnosis applications are available, DN remains a clinical and economic burden. Recent findings showed that noncoding RNAs (ncRNAs) play an important role in DN progression, potentially can be used as biomarkers and therapeutic targets. NcRNAs refers to the RNA species that do not encode for any protein, and the most known ncRNAs are the microRNAs (miRNAs), long noncoding RNAs (lncRNAs), and circular RNAs (circRNAs). Dysregulation of these ncRNAs was reported before in DN patients and animal models of DN. Importantly, there are some interactions between these ncRNAs to regulate the crucial steps in DN progression. Here, we aimed to discuss the reported ncRNAs in DN and their interactions with critical genes in DN progression. Elucidating these ncRNAs regulatory network will allow for a better understanding of the molecular mechanisms in DN and how they can act as new biomarkers for DN and also as the potential targets for treatment.

show abstract

Section: Diabetic Nephropathy Progressionmentioning

confidence: 99%

Interactions Among Non-Coding RNAs in Diabetic Nephropathy

et al. 2020

View full text Add to dashboard Cite

show abstract

“…AngII then combines with AngII receptor to function as a vasoconstrictor -to cause constriction of blood vessels. [30][31][32][33] On the other hand, AngI produces Ang1-7 to inhibit the activity of AngII and therefore to reduce blood pressure. [34][35][36] But it was not found that ZGXFD had an effect on the level of plasma renin (Fig.…”

Section: The Changes In Gut Microbial Composition Of Shr After Drugmentioning

confidence: 99%

Zhengganxifeng Decoction Affects Gut Microbiota and Reduces Blood Pressure <i>via</i> Renin–Angiotensin System

Zhang

Jin

et al. 2019

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Zhengganxifeng decoction (ZGXFD) is a traditional Chinese medicinal formula, from "Medical Zhong parameter West recorded" by Xichun Zhang, which has been applied to the treatment of clinical essential hypertension. Besides its effect in blood pressure reduction, ZGXFD is also known to be a radical therapy with little or no side effects. Compared with western medicines, Chinese medicinal formulas have the advantage of simultaneously attacking multiple targets. However, such a property brings trouble to the pharmacological studies of Chinese medicines. This study investigated the composition of gut microbiota in spontaneously hypertensive rats (SHR) treated with ZGXFD. ZGXFD was shown to cause similar effects in the treatment group as benazepril: both were able to reduce in SHR the microbial diversity, Firmicutes to Bacteroidetes (F/B) ratio and coccus to bacillus (C/B) ratio. Meanwhile, ZGXFD can maintain the integrity of intestinal mechanistic barrier and elevate the percentage of bacteria producing short chain fatty acids (SCFA). By investigating renin-angiotensin system (RAS) system, we found that ZGXFD can decrease the expression of angiotensin-converting-enzyme (ACE) in lungs, which in turn causes a increase in AngI produces angiotensin1-7 (Ang1-7) and decrease in AngII. ZGXFD regulate blood pressure in SHR via RAS.

show abstract

“…1,2 Recent studies have demonstrated a global defect in fatty acid oxidation (FAO) leading to a compromise in the main source of energy for tubular epithelial cells. 10 However, they have been scarcely effective [11][12][13][14] and thus there is urgent need to develop new therapeutic strategies. 3 While there has been significant progress in the understanding of renal fibrogenesis, [6][7][8] no effective therapy is available to prevent its progression or revert tissue damage.…”

Section: Introductionmentioning

confidence: 99%

MiR‐9‐5p protects from kidney fibrosis by metabolic reprogramming

et al. 2019

View full text Add to dashboard Cite

MicroRNAs (miRNAs) regulate gene expression posttranscriptionally and controlbiological processes (BPs), including fibrogenesis. Kidney fibrosis remains a clinical challenge and miRNAs may represent a valid therapeutic avenue. We show that miR-9-5p protected from renal fibrosis in the mouse model of unilateral ureteral obstruction (UUO). This was reflected in reduced expression of pro-fibrotic markers, decreased number of infiltrating monocytes/macrophages, and diminished tubular epithelial cell injury and transforming growth factor-beta 1 (TGF-β1)-dependent dedifferentiation in human kidney proximal tubular (HKC-8) cells. RNA-sequencing (RNA-Seq) studies in the UUO model revealed that treatment with miR-9-5p prevented the downregulation of genes related to key metabolic pathways, including mitochondrial function, oxidative phosphorylation (OXPHOS), fatty acid oxidation (FAO), and glycolysis. Studies in human tubular epithelial cells demonstrated that miR-9-5p impeded TGF-β1-induced bioenergetics derangement. The expression of the FAO-related axis peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1α)-peroxisome proliferator-activated receptor alpha (PPARα) was reduced by UUO, although preserved by the administration of miR-9-5p. We found that in mice null for the mitochondrial master regulator PGC-1α, miR-9-5p was unable to promote a protective effect in the UUO model. We propose that miR-9-5p elicits a protective response to chronic kidney injury and renal fibrosis by inducing | 411 FIERRO-FERNÁNDEZ Et al.

show abstract

Effects of RAAS Inhibitors in Patients with Kidney Disease

Cited by 71 publications

References 33 publications

Interactions Among Non-Coding RNAs in Diabetic Nephropathy

Interactions Among Non-Coding RNAs in Diabetic Nephropathy

Zhengganxifeng Decoction Affects Gut Microbiota and Reduces Blood Pressure <i>via</i> Renin–Angiotensin System

MiR‐9‐5p protects from kidney fibrosis by metabolic reprogramming

Contact Info

Product

Resources

About